More NewsRead More
FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) Oxycodone XR Incorporating PODRAS(TM) Technology
May 26, 2015
Intellipharmaceutics Announces Agreement to Acquire Real Property that Houses its Manufacturing, R&D and Office Facilities in Toronto, Ontario and Status of 5mg Strength of its Generic Focalin XR(R)
May 25, 2015
Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
May 21, 2015
Health Care Sector in Focus: Complementary Research on Great Basin, PhotoMedex, Intellipharmaceutics, Transenterix, and Medovex
April 30, 2015
from PR Newswire
Intellipharmaceutics Reports Director Election Results
April 22, 2015
Intellipharmaceutics Announces First Quarter 2015 Results
April 14, 2015
Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone
March 30, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here